CHARLES H. RAMMELKAMP, M.D.; CHESTER S. KEEFER, M.D., F.A.C.P.
In view of the fact that patients with hemolytic streptococcal infections who are treated with sulfanilamide often continue to have a prolonged and protracted illness, it is desirable to search for more effective chemotherapeutic agents. Recently, another sulfonamide derivative, sulfadiazine, has been described by Roblin, Williams, Winnek, and English.1 In preliminary studies it was found to protect mice against hemolytic streptococcal and pneumococcal infections.2 Later,3 it was reported that it was superior to either sulfanilamide or sulfapyridine in the treatment of experimental infections of mice due to the hemolytic streptococcus. It was pointed out that the animals receiving sulfadiazine had
Learn more about subscription options.
Register Now for a free account.
RAMMELKAMP CH, KEEFER CS. SULFADIAZINE; A STUDY OF ITS EFFECT ON HEMOLYTIC STREPTOCOCCI(SULFADIAZINE; A STUDY OF ITS EFFECT ON HEMOLYTIC STREPTOCOCCI*). Ann Intern Med. 1942;16:659–665. doi: 10.7326/0003-4819-16-4-659
Download citation file:
Published: Ann Intern Med. 1942;16(4):659-665.
Infectious Disease, Streptococcal Infections.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only